1Y Close · As of Aug 26, 2026
BioNote operates in the Pharmaceuticals sector.
Legal name: BioNote, Inc.
In fiscal year 2025, BioNote (377740) reported revenue of 118.3 billion KRW, up 15.1% from 102.8 billion KRW a year earlier.
Operating profit was 16.7 billion KRW and net income was -87.5 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 493.1 billion KRW, with a P/B of 0.33.
These figures can be verified in the DART filing (receipt no. 20260318001576).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 118.3B | 16.7B | -87.5B |
| 2024 | 102.8B | 12.2B | 55.3B |
| 2023 | 90.1B | -47.0B | -20.5B |
Recent Filings
Semi-Annual Report (2026.06)
Consolidated Operating (Preliminary) Earnings (Fair Disclosure)
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: Treasury stock filings in the last 3 years: 1 cancellation(s).
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-08-06 | Consolidated Operating (Preliminary) Earnings (Fair Disclosure) |